Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseMarc S. Sabatine, Terje R. Pedersen, Robert P. Giugliano et al.|New England Journal of Medicine|2017Cited by 6k
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialPeter Sever, Jan Östergren, Björn Dahlöf et al.|The Lancet|2003Cited by 3.8k
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialBjörn Dahlöf, Jan Östergren, Peter Sever et al.|The Lancet|2005Cited by 2.9k
Interpretation of the evidence for the efficacy and safety of statin therapyRory Collins, Richard Peto, Christina Reith et al.|The Lancet|2016Cited by 1.8k
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery DiseaseMarc P. Bonaca, Marc S. Sabatine, Robert P. Giugliano et al.|Circulation|2017Cited by 754